ArticleClinical and experimental nephrology2025
Temporal changes of the life and renal prognoses of patients with rapidly progressive glomerulonephritis in Japan, 1989-2019.
Article in Clinical and experimental nephrology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Association Between Severe Kidney Impairment at Treatment Initiation and Mortality in Patients With Antineutrophil Cytoplasmic Antibody-associated Vasculitis.Kidney medicine · 2026Article
- Long-term outcomes remain unchanged despite reduced glucocorticoid exposure in ANCA-associated vasculitis: the multicentre REVEAL cohort study.Frontiers in immunology · 2026Observational
- Successful reintegration of a very elderly patient with rapidly progressive glomerulonephritis due to microscopic polyangiitis after multidisciplinary treatment: a case report.Frontiers in nephrology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThis study is a continuation of the Japan Rapidly Progressive GlomeruloNephritis (RPGN) Working Group's chronological nationwide survey.
methodsWe analyzed 1,660 RPGN cases from 2016-2019 and compared them to 4,179 cases from five earlier periods (1989-1998, 1999-2001, 2002-2008, 2009-2011, 2012-2015). Data on causative diseases, clinical severity, 24-month life and renal survival, and treatment details were collected and compared.
resultsThe most recent cohort showed an older median age at onset (median age 74 years), with improved serum creatinine levels (median 2.5 mg/dL). Cumulative survival at 24 months remained stable (periods 1989-1998, 1999-2001, 2002-2008, 2009-2011, 2012-2015, 2016-2019 were each 72.0%, 72.9%, 77.7%, 83.0%, 84.9%, 83.5%, p < 0.01), while renal survival showed a favorable trend in the most recent periods (there were each 68.7%, 75.4%, 76.7%, 73.4%, 78.2%, 78.4%, p < 0.01). Anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV)-RPGN had similar outcomes to the overall cohort. Increased rituximab use was observed, with no significant differences in life and renal prognosis between rituximab (RIX) and cyclophosphamide (CY). In severe renal impairment (Cre ≥ 6), renal prognosis was better in the CY or RIX use group than in the non-use group (p = 0.035, 0.025). Anti-glomerular basement membrane disease had a poorer renal prognosis compared to other causes.
conclusionsDespite an increasingly older age of onset, both life and renal prognoses for new-onset AAV-RPGN from 2016 to 2019 remain comparable to the best in previous surveys, due to the impact of constant improvements in early diagnosis and changes in treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.